Number of pages: 100 | Report Format: PDF | Published date: July 21, 2022
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
Report Attribute |
Details |
Market size value in 2021 |
USD 2.45 billion |
Revenue forecast in 2030 |
USD 8.41 billion |
Growth Rate |
CAGR of 14.70 % from 2022 to 2030 |
Base year for estimation |
2021 |
Forecast period |
2022-2030 |
Segments covered |
Treatment Type, End User |
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
The global stomach cancer treatment market was pegged at US$ 2.45 billion in 2021 and is expected to witness a CAGR of 14.70 % during the forecast period.
Market Fundamentals
Stomach cancer also known as gastric cancer is a disorder when the cells in the tissue lining show abnormal growth. Gastric cancer has the fifth highest incidence among all types of cancer, accounting for 5.7 percent of all new cases. The treatments involve chemotherapy, radiotherapy, and even surgery. The risk of stomach cancer is higher in people consuming more processed and spicy foods, alcohol consumption, and smoking. Stomach cancer can occur at a very early age, but the risk of getting affected by this disease grows with age.
[8675343]
Market Dynamics
Increased smoking and excessive alcohol use, a high rate of population with obesity, and consumption of an unhealthy diet are all contributing to the growth of the stomach cancer treatment market. However, the availability of medications to treat stomach cancer is constrained by stringent laws and regulations, which may impede market expansion.
Market Ecosystem
The global stomach cancer treatment market has been analyzed from three perspectives: treatment type, end-user, and region.
Stomach Cancer Treatment Market By Treatment Type
[9765433]
According to treatment type, the global stomach cancer treatment market is grouped into chemotherapy, radiotherapy, immunotherapy, targeted drug therapy, and surgery. Among these, chemotherapy has dominated the global market. Chemotherapy is a useful method to treat cancer; this therapy does not cause any pain when administered and it can shrink the cancer cells or delay their growth, which can make the surgery more effective. However, chemotherapy also has some side effects like the development of chemical resistance to drugs, hair loss, etc. Radiation therapy is also considered one of the widely used therapies in cancer treatment. Radiation therapy in high doses kills carcinogens by damaging their DNA, thus stopping cell division. Hence, radiotherapy is also considered among the most effective methods to treat stomach cancer. Radiation therapy also has some side effects such as a notable risk of disease relapse. On the other hand, immunotherapy is a type of cancer treatment that utilizes the patient’s own immune system to help destroy cancer cells. For stomach cancer, there are currently six FDA (Food And Drug Administration)-approved immunotherapy options. These six treatments include targeted antibodies such as ramucirumab, trastuzumab, trastuzumab deruxtecan, and immunomodulators such as dostarlimab, nivolumab, and pembrolizumab. In, addition the estimate from National Cancer Institute (NCI) states that some patients with advanced stomach (gastric) cancer may live longer if they are treated with the immunotherapy drug nivolumab (OPDIVO) plus chemotherapy as an initial treatment.
Stomach Cancer Treatment Market By End-User
Considering the end-users, the global stomach cancer treatment market is classified into hospitals, specialized cancer treatment centers and ambulatory surgical centers. Among these, patients highly prefer hospitals for cancer treatments. Specialized cancer treatment centers are also witnessing higher patient footfall in the recent years. The WHO (World Health Organization) recommends that every country should aim to have at least one cancer care center that can provide appropriate knowledge with good guidance and treatment. Some of these centers also offer insurance cover and are government-funded which extends economic assistance to the patients.
Stomach Cancer Treatment Market by Region
Regionally, the global stomach cancer treatment market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (Row). Asia Pacific has dominated the global stomach cancer treatment market owing to factors such as the high number of patients suffering from the disease in this region. For instance, according to Globocan in the year 2020, Asia has witnessed 819,994 new cases of stomach cancers that account for 8.6% of total cancer cases, and the number is expected to grow up to 1,397,478 in the next five years. North America is also expected witness significant growth in the global stomach cancer treatment market due to presence of a high number of patients, unhealthy eating habits, increased interest in alcohol and smoking, large pool of geriatric population, which is more prone to various cancer types. The American Cancer Society reports that adult populations are more likely to get stomach cancer. Europe region is also showing significant growth in the forecast period. The factors contributing to this growth include the launch of new diagnosis and treatment solutions, sudden shifts in lifestyles, and increased research, and development initiatives.
Competitive Landscape
Some of the prominent players operating in the global stomach cancer treatment market include:
Strategic Developments
The global stomach cancer treatment market was anticipated to clock US$ 2.45 billion in 2021
The stomach cancer treatment market is projected to reach US$ 8.41 billion by 2030
The global stomach cancer treatment market is mainly driven by increased smoking and excessive alcohol use.
Eli Lilly and Company, Novartis International AG, Merck & Co. Inc., F. Hoffman La-Roche Ltd., Otsuka Pharmaceutical Co. Ltd, Bayer AG, Celltrion Inc., Tahio Pharmaceutical Co. Ltd., Bristol-Myers Squibb Co., and Ipsen pharma S.A. among others.
The growth rate of stomach cancer treatment market is CAGR of 14.70 % between 2022-2030.
North America held the largest market share of the global stomach cancer treatment market.
*Insights on financial performance is subject to availability of information in public domain